Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 20/20 | 1.00 |
| ▸ | CHRM4 | P08173 | 20/20 | 1.00 |
| ▸ | CHRM5 | P08912 | 20/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 20/20 | 1.00 |
| ▸ | CHRM3 | P20309 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7398778 | 0.81 | CHRM2 (1.00) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL1063755 | 0.77 | CHRM2 (1.00) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL1062439 | 0.77 | CHRM2 (0.72) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL4692117 | 0.77 | CHRM2 (1.00) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL7396408 | 0.72 | CHRM2 (1.00) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL4693893 | 0.72 | CHRM2 (1.00) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL30036439 | 0.70 | MAOB (0.63) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL103158 | 0.70 | MAOB (0.63) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL3225393 | 0.70 | CHRM2 (0.53) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL7398654 | 0.69 | CHRM2 (1.00) | CHRM2CHRM4CHRM5CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0640082-A1 | HETEROAROMATIC QUINUCLIDINENES, THEIR USE AND PREPARATION | Pharmacia & Upjohn Aktiebolag (SE) | 1995-03-01 | — | — | EP | claimed |
| WO-1993023395-A1 | HETEROAROMATIC QUINUCLIDINENES, THEIR USE AND PREPARATION | KABI PHARMACIA AB (SE) | 1993-11-25 | — | — | WO | claimed |
| US-20080132704-A1 | 3-Substituted quinuclidines and their use | PETERS DAN | 2008-06-05 | — | — | US | disclosed |
| US-7332507-B2 | 3-substituted quinuclidines and their use | NEUROSEARCH A/S (DK) | 2008-02-19 | — | — | US | disclosed |
| EP-1339712-B1 | 3-SUBSTITUTED QUINUCLIDINES AND THEIR USE AS NICOTINIC AGONISTS | NEUROSEARCH AS (DK) | 2008-02-06 | — | — | EP | disclosed |
| EP-1513839-B1 | 3-SUBSTITUTED QUINUCLIDINES AND THEIR USE | NEUROSEARCH AS (DK) | 2006-07-26 | — | — | EP | disclosed |
| US-20050176756-A1 | 3-Substituted quinuclidines and their use | NEUROSEARCH A/S (DK) | 2005-08-11 | — | — | US | disclosed |
| US-6884807-B2 | 3-substituted quinuclidines and their use as nicotinic agonists | NEUROSEARCH, A/S (DE) | 2005-04-26 | — | — | US | disclosed |
| EP-1513839-A1 | 3-SUBSTITUTED QUINUCLIDINES AND THEIR USE | NEUROSEARCH A/S (DK) | 2005-03-16 | — | — | EP | disclosed |
| US-20040044026-A1 | 3-Substituted quinuclidines and their use as nicotinic agonists | ANIONA APS (DK) | 2004-03-04 | — | — | US | disclosed |
| WO-2003101987-A1 | 3-SUBSTITUTED QUINUCLIDINES AND THEIR USE | NEUROSEARCH A/S (DK) | 2003-12-11 | — | — | WO | disclosed |
| EP-1339712-A1 | 3-SUBSTITUTED QUINUCLIDINES AND THEIR USE AS NICOTINIC AGONISTS | NEUROSEARCH A/S (DK) | 2003-09-03 | — | — | EP | disclosed |
| WO-2002044176-A1 | 3-SUBSTITUTED QUINUCLIDINES AND THEIR USE AS NICOTINIC AGONISTS | NEUROSEARCH A/S (DK) | 2002-06-06 | — | — | WO | disclosed |
| US-5599937-A | Heteroaromatic quinuclidinenes, their use and preparation | PHARMACIA AB (SE) | 1997-02-04 | — | — | US | disclosed |
| EP-0640082-A1 | HETEROAROMATIC QUINUCLIDINENES, THEIR USE AND PREPARATION | Pharmacia & Upjohn Aktiebolag (SE) | 1995-03-01 | — | — | EP | disclosed |
| WO-1993023395-A1 | HETEROAROMATIC QUINUCLIDINENES, THEIR USE AND PREPARATION | KABI PHARMACIA AB (SE) | 1993-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176756-A1 | 3-Substituted quinuclidines and their use | CHRNA3, CHRNA5, CHRNA6 | CHRM2 20/4885CHRM4 19/4885CHRM5 12/4885 |
| US-20040044026-A1 | 3-Substituted quinuclidines and their use as nicotinic agonists | CHRNA3, CHRNA5, CHRNA7 | CHRM2 23/4885CHRM4 20/4885CHRM5 17/4885 |
| US-20080132704-A1 | 3-Substituted quinuclidines and their use | CHRNA3, CHRNA5, CHRM3 | CHRM2 20/4885CHRM4 21/4885CHRM5 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.